Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lexatumumab + interferon gamma 1b
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Lexatumumab + interferon gamma 1b is an experimental combination therapy investigated by the National Cancer Institute (NCI) for the treatment of refractory pediatric solid tumors, including Ewing's sarcoma, osteosarcoma, neuroblastoma, and rhabdomyosarcoma. Lexatumumab (HGS-ETR2) is a fully human monoclonal antibody that acts as an agonist for TRAIL receptor 2 (DR5), inducing apoptosis in tumor cells. However, many pediatric tumors exhibit resistance to TRAIL-mediated apoptosis due to low expression of caspase-8. Interferon gamma 1b, a recombinant cytokine, is added to the regimen to upregulate caspase-8 expression, thereby restoring the sensitivity of the tumor cells to lexatumumab-induced cell death. This synergistic approach was evaluated in a Phase I dose-escalation trial (NCT00428272).
- Brand names
- Actimmune
- Other names
- HGS-ETR2 + interferon gamma 1blexatumumab + Actimmunelexatumumab + IFN-gamma 1b
02
Targets
IFNGR1 (Interferon gamma receptor 1)TNFRSF10B (DR5)
Beyond the preview
Go deeper on lexatumumab + interferon gamma 1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lexatumumab + interferon gamma 1b.